Scarica l'app Stockscreener
1.25
3.85%
-0.05
Pre-mercato:
1.25
Precedente Chiudi:
$1.30
Aprire:
$1.28
Volume 24 ore:
206.49K
Relative Volume:
0.06
Capitalizzazione di mercato:
$29.29M
Reddito:
-
Utile/perdita netta:
$-178.01M
Rapporto P/E:
-0.1501
EPS:
-8.326
Flusso di cassa netto:
$-7.87M
1 W Prestazione:
+5.93%
1M Prestazione:
+6.84%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$1.20
$1.2899
Intervallo di 1 settimana:
$1.1101
$1.33
Portata 52W:
$0.81
$1.66
Lunai Bioworks Inc Stock (LNAI) Company Profile
Nome
Lunai Bioworks Inc
Settore
Industria
Telefono
45 39179840
Indirizzo
CENTURY CITY MEDICAL PLAZA, SUITE 906 LOS ANGELES
Confronta LNAI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LNAI
Lunai Bioworks Inc
|
1.25 | 30.46M | 0 | -178.01M | -7.87M | -8.326 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lunai Bioworks Inc Borsa (LNAI) Ultime notizie
Lunai Bioworks (LNAI) Stock Analysis Report | Financials & Insights - Benzinga
Lunai Bioworks enters sales agreement with Dawson James SecuritiesSEC filing - marketscreener.com
Lunai Bioworks Enters Sales Agreement with Dawson James - TipRanks
Does Lunai Bioworks Inc (LNAI) offer a good opportunity for investors? - Setenews
Lunai Bioworks’ immune cell therapy shows tumor regression, wins first license - MSN
Lunai Bioworks stock soars after securing first licensing deal for cancer therapy - MSN
Lunai Bioworks - The Pharma Letter
Lunai Bioworks lands first licensing deal for off-the-shelf cancer immunotherapy - The Pharma Letter
There is no way Lunai Bioworks Inc (LNAI) can keep these numbers up - Setenews
Lunai Bioworks Inc (2Q50.MU) latest stock news and headlines - Yahoo Finance Australia
Lunai Bioworks Inc. (LNAI) -7.5% in After-hours: Shares Decline Amidst New Licensing Agreement - Stocks Telegraph
Lunai Bioworks Secures $3.1M in Private Placement - TipRanks
Lunai Bioworks sells 3,133,333 shares in private financing deal - Stock Titan
LNAI Stock: Surging or Slipping? - StocksToTrade
Lunai Bioworks (LNAI) Stock: Plummets 14.2% Despite Breakthrough in Cancer Immunotherapy - parameter.io
Lunai Bioworks Shares Rise After Company Secures Licensing Intent for Dendritic Cell Therapy - marketscreener.com
Lunai Bioworks: Stock Surge or Bubble? - timothysykes.com
Lunai Bioworks stock soars after securing first licensing deal for cancer therapy By Investing.com - Investing.com South Africa
LNAI's Groundbreaking Immune Cell Therapy Advances with Key Lice - GuruFocus
Lunai Bioworks Secures First Licensing LOI Following Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models - MarketScreener
Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models - Yahoo Finance
Lunai Bioworks rises on early licensing interest in DCCT therapy | Tap to know more | Inshorts - Inshorts
Lunai Bioworks Inc. (LNAI) -7.5% in After-hours: Routine Trading Amid Price Decline - Stocks Telegraph
Lunai Bioworks Inc (2Q50.MU) options chain - Yahoo Finance Australia
Lunai Bioworks Inc. (LNAI) -13.9% in Normal Trading: Price Declines Amid Routine Trading - Stocks Telegraph
What is the current Price Target and Forecast for Lunai Bioworks Inc. (LNAI) - Zacks Investment Research
Lunai Bioworks Inc. announced that it expects to receive $3.133333 million in funding - marketscreener.com
Lunai Bioworks Inc Com (LNAI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Lunai Bioworks Inc (2Q50.MU) analyst ratings, estimates and forecasts - Yahoo Finance Australia
Lunai Bioworks Inc (2Q50.MU) Valuation Measures & Financial Statistics - Yahoo! Finance Canada
Are Smart Investors Making the Right Decision? Lunai Bioworks Inc (LNAI) - Setenews
Lunai Bioworks Inc. Unveils Transformer Platform to Secure Generative AI and Accelerate Drug Discovery - Greenville Online
Lunai Bioworks Inc. (LNAI) stock price, news, quote and history - Yahoo Finance Australia
Lunai Bioworks: Fiscal Q1 Earnings Snapshot - New Haven Register
Lunai Bioworks Inc. Reports Earnings Results for the First Quarter Ended September 30, 2025 - MarketScreener
[10-Q] Lunai Bioworks Inc. Quarterly Earnings Report | RENB SEC FilingForm 10-Q - Stock Titan
A better buy-in window may exist right now for Lunai Bioworks Inc (LNAI) - Setenews
A Mandatory Rebranding: Lunai Bioworks Emerges from Enochian’s Ashes - Ad-hoc-news.de
Lunai Bioworks Inc. (2Q50.F) Company Profile & Facts - Yahoo! Finance Canada
Lunai Bioworks Inc. (LNAI) Stock Major Holders - Yahoo! Finance Canada
Top Biotech Stocks To Follow NowNovember 5th - MarketBeat
Lunai Bioworks Inc. (LNAI) Stock Forecast & Price Prediction 2025–2030 - CoinCodex
Lunai Bioworks Inc. (LNAI) latest press releases and corporate news - Yahoo Finance UK
Top Biotech Stocks To Follow Now – November 5th - Defense World
Lunai Bioworks Inc (2Q50.MU) Latest Press Releases & Corporate News - Yahoo! Finance Canada
[8-K] Lunai Bioworks Inc. Reports Material Event | RENB SEC FilingForm 8-K - Stock Titan
Lunai Bioworks Inc. (LNAI) stock historical prices and data - Yahoo Finance UK
Lunai Bioworks Inc. (LNAI) interactive stock chart - Yahoo Finance UK
Lunai Bioworks Inc. (LNAI) Stock Price, News, Quote & History - Yahoo! Finance Canada
This trade activity should not be overlooked: Lunai Bioworks Inc (LNAI) - Setenews
Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthro - ANP Persportaal
Lunai Bioworks Inc Azioni (LNAI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.44%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):